Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

NCT01886820 is registered in ClinicalTrials.gov with Navidea Biopharmaceuticals as lead sponsor.

NCT NCT01886820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01886820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology
Lead sponsor
Navidea Biopharmaceuticals
Phase
Phase 3
Overall status
Unknown status
Start date
June 30, 2013
Completion date
September 30, 2018
Enrollment
290 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, dementia